SOURCE: Insulet Corporation

Insulet Corporation

October 20, 2010 16:15 ET

Insulet Ranked Third Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500™

The Omnipod System's Innovative Tubeless Design Drove 131,964% Revenue Growth Over Five Years

BEDFORD, MA--(Marketwire - October 20, 2010) - Insulet Corporation (NASDAQ: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, today announced that it has been ranked third on the Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period from 2005-2009. During this period, Insulet Corporation's revenue grew by 131,964 percent. 

"We are honored to receive this prestigious award that recognizes the tremendous growth Insulet has delivered in the last five years," said Duane DeSisto, President & Chief Executive Officer of Insulet Corporation. "There are now over 20,000 people using the OmniPod System, which is a testament to both its appealing, tubeless design and the dedication of the Insulet team in driving adoption across the country."

"Insulet Corporation and the other 2010 Technology Fast 500™ winners forged ahead in a challenging economic environment to realize exceptional growth," said Phil Asmundson, vice chairman and Deloitte's U.S. technology, media and telecommunications leader. "Deloitte commends Insulet Corporation for this impressive accomplishment."

For additional detail on the Technology Fast 500™ including selection and qualifying criteria, visit www.fast500.com

About the OmniPod Insulin Management System
The OmniPod Insulin Management System is the world's first tubing-free insulin pump. OmniPod offers people living with insulin-requiring diabetes all the benefits of insulin pump therapy, with unprecedented freedom, comfort and ease. OmniPod has just two components: the small, discreet, waterproof Pod, worn almost anywhere on the body to hold and deliver insulin; and the PDM (Personal Diabetes Manager), a hand-held device that communicates wirelessly to program the Pod, calculates suggested doses and has a built-in FreeStyle® blood glucose meter. For more information, please visit: www.myomnipod.com

About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

Contact Information

  • Contact:
    Stephanie Marks for Insulet Corporation
    Email Contact
    212-843-0211